Back to Archived News
Lifeline Biotechnologies, Inc. Files Patent for Improved First Warning Diagnostic System and Launches Partner Search
Wednesday, September 10, 2008
Reno, NV -- Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), a developer of innovative medical technology, today announced that it has filed the patent application on its new neural network diagnostic system. As previously announced, Lifeline has been working diligently with a prominent Asian university to further develop and enhance the company's First Warning System™. This patent application is the result of that extensive work.
According to Dr. Louis Keith, emeritus professor of obstetrics and gynecology at the Feinberg School of Medicine at Northwestern University, "We can now determine which of the thermal aberrations the First Warning System detects is similar to those associated with known cancers. Using a combination of five neural network constructions, we have broken this illusive barrier. This new system has the ability to provide us with 100% selectivity, finding all areas in the breast which generate abnormal thermal signals and, with specificity in the low nineties, correctly classifying them in terms of their similarity to signals obtained from patients with known cancers. This system will continue to improve in its accuracy over time because it learns from each new case presented to it."
Jim Holmes, Lifeline’s CEO, stated, "This effort represents extensive collaboration between Lifeline Biotechnology and two university professors who are renowned experts in thermal analysis and biotechnology. The new system utilizes five different types of neural network in tandem, a technique which has never been used to untangle the thermal information collected by the First Warning System™."
Mr. Holmes went on to say, "Now that we have filed this patent application with the USPTO, we have begun the search for a strategic partner in earnest. We believe that a strategic partner will be better able to establish the First Warning System in the marketplace."
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: the development of the First Warning System™’s interpretive, proprietary software, clinical trials and FDA pre-marketing clearance and the product is successfully established in the marketplace.
Lifeline competes in the money markets for funds to support the development of its product. The cost of funds for early-stage companies like Lifeline are expensive, and the terms have been, and may continue to be, dilutive. www.lbti.com
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.
Back to Archived News